ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2924

Does the Degree of Decline in Walking Speed Predict Mortality Risk Beyond the Present Level of Walking Speed in Knee Osteoarthritis?

Hiral Master1, Tuhina Neogi 2, Lavalley Michael 3, Louise Thoma 4, Dana Voinier 5, Meredith Christiansen 5, Jason Jakiela 5, Lauren Neely 5 and Daniel White 1, 1University of Delaware, Newark, DE, 2Boston University School of Medicine, Boston, MA, 3Boston University, Boston, 4University of North Carolina at Chapel Hill, Newark, 5University of Delaware, Newark

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: decline, mortality and osteoarthritis, walking speed

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 13, 2019

Title: 6W026: Epidemiology & Public Health (2924–2929)

Session Type: ACR/ARP Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Slow walking speed (WS) is a risk factor for mortality in well-functioning older adults and speeds slower than (< ) 1.22 meters per second (m/s) are a risk factor for poor health outcomes in knee osteoarthritis (OA). WS is known to decline with age, with some declining faster than other, though it is unclear if the rate of decline in WS is additionally relevant for mortality risk in knee OA. If so, considering the degree of decline over a prior year in addition to the present level of WS may be important. Therefore, the purpose of this study was to investigate whether WS at one time-point, degree of decline in WS over past one year, or both predict mortality risk over 9 years in knee OA.

Methods: We used data from the Osteoarthritis Initiative. WS was measured from a 20-m walk test at baseline and the 12-month visit. The index date for this analysis is the 12-month visit. Walking < 1.22 m/s represents the inability to cross a street with a timed crosswalk, and change >0.08 m/s is considered to be a clinically meaningful decline. We classified people into one of four groups depending on the WS at one time-point (the 12-month visit) and degree of decline over the previous year (from baseline to 12-month visit): [1] < 1.22 m/s and >0.08 m/s decline, [2] at least ( >) 1.22 m/s and >0.08 m/s decline, [3] < 1.22 m/s and < 0.08 m/s decline or [4] >1.22 m/s and >0.08 m/s decline. Mortality was assessed up to 9 years of follow-up. We used Kaplan-Meier curves to determine the survival probability for the four groups. We examined the association of the 4 groups with mortality using Cox proportional hazards regression, adjusting for potential confounders.

Results: Of 4229 participants in the analytic sample (58% female, age 62.3±9.2 years, BMI 28.5±4.8 kg/m2), 6% (n=270) died over 9 years. Groups with WS < 1.22 m/s at one time-point were at higher risk of mortality irrespective of history of decline in WS (Figure). Those walking < 1.22 m/s with and without decline had 108% and 96% greater risk of mortality compared with those walking >1.22 m/s without meaningful decline over previous year (Table). Those walking ≥1.22 m/s with decline had a lower risk of mortality than the group walking ≥1.22m/s without meaningful decline in WS, likely related to the latter having started with a higher WS at baseline.

Conclusion: Walking slower than 1.22 m/s was associated with increased mortality risk, irrespective of degree of decline in WS in adults with knee OA. Those walking at least 1.22 m/s who had a meaningful decline in WS over the prior year, did not have increased risk of mortality, and in fact had nonsignificant lower risk, suggesting a potential threshold effect such that WS assessed at one time-point may be sufficient to gauge mortality risk.

Figure: Kaplan-Meier survival curves for adults with knee OA who were classified into one of four groups depending on the walking speed at one time-point -the 12-month visit- and degree of decline over the previous year -from baseline to 12-month visit-.

Table: Association of walking speed measured at one time-point and decline over past one year with the risk of mortality over 9 years among all the study participants -N=4229-.


Disclosure: H. Master, None; T. Neogi, MerckSerono, 5, Novartis, 5; L. Michael, None; L. Thoma, None; D. Voinier, None; M. Christiansen, None; J. Jakiela, None; L. Neely, None; D. White, None.

To cite this abstract in AMA style:

Master H, Neogi T, Michael L, Thoma L, Voinier D, Christiansen M, Jakiela J, Neely L, White D. Does the Degree of Decline in Walking Speed Predict Mortality Risk Beyond the Present Level of Walking Speed in Knee Osteoarthritis? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/does-the-degree-of-decline-in-walking-speed-predict-mortality-risk-beyond-the-present-level-of-walking-speed-in-knee-osteoarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-the-degree-of-decline-in-walking-speed-predict-mortality-risk-beyond-the-present-level-of-walking-speed-in-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology